The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia

Current Hematologic Malignancy Reports

Volumn 7, Issue 2, 2012, Pages 144-152

  Kebriaei, Partow ^a   Poon, L M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell transplantation; Cord blood transplantation; Haplo identical stem cell transplantation; Minimal residual disease; Philadelphia chromosome positive ALL; Reduced intensity transplant regimen

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; HUMAN; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; PATIENT SELECTION; TREATMENT INDICATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84860836661     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0116-3     Document Type: Article

References (72)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. NEngl J Med. 2006;354 (2):166-78. (Pubitemid 43076714)
2. Thomas X, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22 (20):4075-86. (Pubitemid 41185176)
3. Kantarjian H, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101 (12):2788-801. (Pubitemid 39603187)
4. Gokbuget N, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14 (6):1307-25. ix.
5. Rowe JM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106 (12):3760-7. (Pubitemid 41739010)
6. Baker KS, et al. Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia. 2010;24 (12):2039-47.
7. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339 (9):605-15. (Pubitemid 28385659)
8. Marks DI, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114 (25):5136-45.
9. Czuczman MS, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999;93 (11):3931-9. (Pubitemid 29249842)
10. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2006:133-41.
11. Moorman AV, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109 (8):3189-97. (Pubitemid 46572503)
12. Bruggemann M, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107 (3):1116-23. (Pubitemid 43156313)
13. Patel B, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2009;148 (1):80-9.
14. Gokbuget N. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. American Society of Hematology Annual meeting 2009. Oral session, Abstract 12.
15. Ribera JM. Treatment of High-Risk (HR) Philadelphia chromosome-negative (Ph-) adult Acute Lymphoblastic Leukemia (ALL) according to baseline risk factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 trial including the use of Propensity Score (PS) method to reduce assignment bias. In American Society of Hematology 2009. 2009.
16. Goldstone AH, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111 (4):1827-33. Largest prospective study on efficacy of alloHSCT as consolidation therapy in patients with ALL, and largest study which showed that standard-risk patients benefit most from transplant. (Pubitemid 351451489)
17. Hunault M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104 (10):3028-37. (Pubitemid 39507116)
18. Labar B, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients
19. Ribera JM, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90 (10):1346-56.
20. Sebban C, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French group of therapy of adult acute lymphoblastic leukemia. J Clin Oncol. 1994;12 (12):2580-7. (Pubitemid 24379642)
21. Takeuchi J, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002;16 (7):1259-66.
22. Paulson K, Szwajcer D, Seftel MD. The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Transfus Apher Sci. 2011;44 (2):197-203.
23. Cornelissen JJ, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus nodonor comparison. Blood. 2009;113 (6):1375-82.
24. Yanada M, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer. 2006;106 (12):2657-63.
25. Ram R, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer. 116 (14):3447-57.
26. Pidala J, et al. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011;10:CD008818. This was the largest meta-analysis which included 14 trials consisting of 3157 patients and which showed that patients >15 years old, in donor-group had superior overall survival, disease-free survival, and reduced relapse rates but increased risks of non-relapse mortality as compared to the no-donor group.
27. Bassan R, Lerede T, Barbui T. Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. Haematologica. 1996;81 (1):20-36. (Pubitemid 28020251)
28. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15 (1):163-205. (Pubitemid 32201872)
29. Oriol A, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive riskadapted trials by the PETHEMA Study Group. Haematologica. 95 (4):589-96.
30. Tavernier E, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA- 94 trial. Leukemia. 2007;21 (9):1907-14. (Pubitemid 47299963)
31. Martino R, et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21 (10):1023-7. (Pubitemid 28230667)
32. Thomas DA, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86 (7):1216-30. (Pubitemid 29447005)
33. Terwey TH, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant. 2008;42 (12):791-8.
34. Cornelissen JJ, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graftversus- leukemia effect and risk factors determining outcome. Blood. 2001;97 (6):1572-7. (Pubitemid 32217219)
35. Doney K, et al. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2003;9 (7):472-81. (Pubitemid 38351805)
36. Marks DI, et al. The outcome of full-intensity and reducedintensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116 (3):366-74. Large registry data from the CIBMTR, looking at differences between RIC and myeloablative SCT for treatment of Philadelphia-negative ALL. Although findings suggest conditioning intensity did not affect transplantationrelated mortality or relapse risks, this may have been affected by selection bias associated with a retrospective review.
37. Clavert A, et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non- Hodgkin lymphoma. Leuk Lymphoma. 2010;51 (8):1502-8.
38. Arnold R, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16 (12):2423-8. (Pubitemid 36054377)
39. Stein AS, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009;15 (11):1407-14.
40. Cho BS, et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of . The Graft-versus- leukemia a prospective phase 2 study. Leukemia. 2009;23 (10):1763-70.
41. Ram R, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96 (8):1113-20.
42. Santarone S, et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transplant. 2011;17 (10):1505-11.
43. Russell JA, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY totalbody irradiation, and thymoglobulin. Biol Blood Marrow Transplant. 2007;13 (7):814-21. (Pubitemid 46902436)
44. Bachanova V, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113 (13):2902-5.
45. Kiehl MG, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22 (14):2816-25. (Pubitemid 41079899)
46. Ringden O, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113 (13):3110-8. Large registry data from CIBMTR showing similar relapse rates/NRM and LFS after alloHCT from MUD compared to MSD in ALL patients.
47. Lee S, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13 (9):1083-94. (Pubitemid 47215565)
48. Dahlke J, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37 (2):155-63. (Pubitemid 43108807)
49. Laughlin MJ, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. NEngl J Med. 2004;351 (22):2265-75. (Pubitemid 39552742)
50. Rocha V, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351 (22):2276-85. (Pubitemid 39552743)
51. Eapen M, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 11 (7):653-60. One of the largest registry data demonstrating that leukemia-free survival after unrelated cord blood transplantation is comparable to that after 8/8 and 7/8 allele matched transplant, hence supporting the use of unrelated cord blood for patients with acute leukemia when there is no HLA matched unrelated adult donor available.
52. Tomblyn MB, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009;27 (22):3634-41.
53. Ciceri F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112 (9):3574-81.
54. Luznik L, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2008;14 (6):641-50. (Pubitemid 351664058)
55. Luznik L, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 115 (16):3224-30.
56. Giebel S, et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant. 2010;45 (6):1095-101.
57. Wetzler M, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93 (11):3983-93. (Pubitemid 29249848)
58. Laport GG, et al. Long-term remission of Philadelphia chromosomepositive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112 (3):903-9.
59. Snyder DS, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia. 1999;13 (12):2053-8.
60. Fielding AK, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113 (19):4489-96.
61. Thomas DA, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103 (12):4396-407. (Pubitemid 38745962)
62. Tanguy-Schmidt A, et al. Long-term results of the Imatinib GRAAPH-2003 study in newly-diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. ASH Annu Meet Abstr. 2009;114 (22):3080.
63. Fielding AK, et al. Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia; Final results of the UKALLXII/ECOG2993 trial. ASH Annu Meet Abstr. 2010;116 (21):169.
64. de Labarthe A, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109 (4):1408-13. (Pubitemid 46239571)
65. Yanada M, et al. High complete remission rate and promising outcome by combination of Imatinib and chemotherapy for newly diagnosed BCR-ABLâ"Positive acute lymphoblastic eukemia: aphase II study by the Japan adult leukemia study group. J Clin Oncol. 2006;24 (3):460-6. (Pubitemid 46630465)
66. Pfeifer H, et al. Long-term outcome of 335 adult patients receiving different schedules of Imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). ASH Annu Meet Abstr. 116 (21):173-.
67. Ravandi F, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116 (12):2070-7.
68. Foa R, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118 (25):6521-8.
69. Wassmann B, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106 (2):458-63. (Pubitemid 40981238)
70. Kebriaei P, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2011 Epub.
71. Wassmann B. Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia: interim results of a randomized phase III GMALL study. Bone Marrow Transplant. 2009;43:S48.
72. Ribera JM, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 95 (1):87-95.